CTLA4 and neoplasm: Some studies have shown that stimulating the ICOS pathway markedly enhances the efficacy of CTLA-4 blockade in cancer immunotherapy, while inhibiting the ICOS pathway reduces the efficacy of anti-CTLA-4 drugs and reduces tumor rejection [30, 31].